Engineered NK cells are emerging as scalable, safer cancer therapies with early clinical success and massive market growth.
Here, James C. Lo & team identify FAM20C as a key mediator of obesity-induced adipocyte dysfunction and inflammation, suggesting its inhibition as a potential therapy for Type2 Diabetes:
The figure shows visceral white adipose tissue in mice with adipocyte-specific deletion of Fam20c shifts shows lower macrophage area compared with controls.
1Division of Cardiology, Department of Medicine, Weill Center for Metabolic Health, Cardiovascular Research Institute, and.
2Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
3Helmholtz Institute for Metabolic, Obesity, and Vascular Research, Helmholtz Center Munich, University of Leipzig and University Hospital Leipzig, Leipzig, Germany.
A new CRISPR breakthrough shows scientists can turn genes back on without cutting DNA, by removing chemical tags that act like molecular anchors. The work confirms these tags actively silence genes, settling a long-running scientific debate. This gentler form of gene editing could offer a safer way to treat Sickle Cell disease by reactivating a fetal blood gene. Researchers say it opens the door to powerful therapies with fewer unintended side effects.
In early life, astrocytes help to mold neural pathways in response to the environment. In adulthood, however, those cells curb plasticity by secreting a protein that stabilizes circuits, according to a mouse study published last month in Nature.
âItâs a new and unique take on the field,â says Ciaran Murphy-Royal, assistant professor of neuroscience at Montreal University, who was not involved in the study. Most research focuses on how glial cells drive plasticity but ânot how they apply the brakes,â he says.
Astrocytes promote synaptic remodeling during the development of sensory circuits by secreting factors and exerting physical controlâin humans, a single astrocyte can clamp onto 2 million synapses, previous studies suggest. But the glial cells are also responsible for shutting down critical periods for vision and motor circuits in mice and fruit flies, respectively.
It has been unclear whether this loss of plasticity can be reversed. Some evidence hints that modifying the neuronal environmentâthrough matrix degradation or transplantation of young neuronsâcan rekindle flexibility in adult brains.
The new findings confirm that in adulthood, plasticity is only dormant, rather than lost entirely, says Nicola Allen, professor of molecular neurobiology at the Salk Institute for Biological Studies and an investigator on the new paper. âNeurons donât lose an intrinsic ability to remodel, but that process is controlled by secreted factors in the environment,â she says.
Specifically, astrocytes orchestrate that dormancy by releasing CCN1, a protein that stabilizes circuits by prompting the maturation of inhibitory neurons and glial cells, Allenâs team found. The findings suggest that astrocytes have an active role in stabilizing adult brain circuits.
The loss of plasticity in adulthood is often seen as a âsad feature of getting older,â says Laura Sancho Fernandez, project manager in Guoping Fengâs lab at the Massachusetts Institute of Technology, who worked on the study as a postdoctoral researcher in Allenâs lab. âBut itâs really important for maintaining stable representations and circuits in the brain.â
A research group led by Professor Michael Glickman, dean of Technionâs Faculty of Biology, has uncovered a key mechanism in the development of Alzheimerâs. The mechanism in question identifies toxic proteins and disposes of them.
In most cases, harmful proteins are degraded inside the cell. However, the researchers found that in certain situations, the very system meant to eliminate these proteins simply transfers them outside the cell. This discovery may explain how a disease that begins randomly in individual neurons can spread to large regions of the brain.
The study, published in Proceedings of the National Academy of Sciences, was led by Prof. Glickman and postdoctoral researcher Dr. Ajay Wagh. In their article, they describe how brain cells deal with UBB+1, a defective and toxic variant of the protein ubiquitin.
Exciting to see this modern genomic approach to classification of psychiatric disorders! Hopefully this will eventually lead to potential new gene therapy targets for treatment.
Analysis of more than one million people shows that mental-health disorders fall into five clusters, each of them linked to a specific set of genetic variants.
RCT: Smartphone-based ecological momentary assessment found greater morning fatigue but reduced afternoon and evening fatigue in patients with Insomnia treated with suvorexant vs placebo.
Question What is the effect of insomnia suvorexant pharmacotherapy on daytime insomnia symptoms as assessed via smartphone ecological momentary assessment (EMA)?
Findings In this randomized clinical trial that included 40 older adults with insomnia, traditional outcomes assessments detected differences between suvorexant and placebo groups in daytime insomnia symptoms; however, EMA was sensitive to detect effects of insomnia pharmacotherapy at various times of day.
Meaning These findings suggest that EMA warrants further refinement in sleep and psychiatric research and clinical care.